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What FactorS are aSSociated With increaSing chargeS For Major 
joint rePlaceMentS BetWeen 2008 and 2011?
Chiu G.R, Dong X., Wang Z., Meckley L.M., Miyasato G.
Trinity Partners, LLC, Waltham, MA, USA
Objectives: This study measured the association between hospital characteristics 
and changes in hospital charges for major joint replacement (MJR). MethOds: 
2008 and 2011 hospital charge and reimbursement data were obtained from MJR 
inpatient Medicare claims. Multivariate linear regression models were used at the 
hospital level to regress the percent change in hospital charges on hospital charac-
teristics which included hospital demographics and MJR patient summary meas-
ures. Independent variables represented both baseline 2008 and change in value/
status quantities. Results: The analysis included 3,016 hospitals. In multivariate 
models, many hospital characteristics were significantly associated with the per-
cent change in charges. Hospital type and census region were significantly related 
to percent change in charges. Specifically, Government and Non-Profit hospitals 
experienced smaller charge increases than Proprietary hospitals (-5.5% and -4.5% 
respectively, p< 0.0001). Compared to the Northeast, the West, South, and Midwest 
experienced 5.5%, 4.4%, and 3.3% increases in charges on average (p≤ 0.001), while 
the Midwest, West, and South were not statistically significantly different from each 
other (p> 0.05). Also, a one-day increase in the average length of stay was associ-
ated with an average charge increase of 6.7% (p< 0.0001). Overall, the final model 
accounted for 9% of the total variance. cOnclusiOns: Hospital characteristics, 
such as the region and type, as well as changes to average length of stay between 
2008 and 2011 were strong predictors of percent change in average charge for MJR. 
While several other factors were also statistically significantly related to change 
in charges for MJR, small effect sizes were not practically meaningful. The small 
percent of variance explained by the model leads us to conclude there are other 
factors not captured by Medicare data that are additionally responsible for growth 
in health care costs.
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Objectives: To evaluate health care costs and medication use patterns (persistence, 
discontinuation and switching) in patients with rheumatoid arthritis (RA) on etaner-
cept (ETN), infliximab (IFX) or adalimumab (ADA) in Texas Medicaid. MethOds: 
Prescription and medical claims for Texas Medicaid beneficiaries (18-63 years) 
with an RA diagnosis (ICD-9-CM code 714.0x) without claims for a biologic agent 
in the 6-months pre-index (July 1, 2003 to December 31, 2010) were analyzed over 
an 18-month study period between July 1, 2003 and August 31, 2011 (6-month 
pre- and 12-month post-index) based on their index biologic (ADA, ETN, or INF). 
The primary outcomes were 1-year persistence, discontinuation, switching and 
health care costs (RA-related and TNF inhibitor costs) to Texas Medicaid post-index, 
adjusted to 2011 US dollars using the medical consumer price index. Cohorts were 
constructed using propensity score (PS) matching controlling for baseline differ-
ences in demographics and clinical characteristics. Results: After PS matching, 
822 patients (n= 274/biologic group) comprised the final sample. The mean age (±SD) 
was 48.9 (±9.8) years, and the majority (69.2%) were between age 45 and 63, Hispanic 
(53.7%) and female (88.0%). Post-index mean (±SD) total health care costs were 
$16,477 (±$9,228), RA-related costs were $13,713 (±$8,309) and TNF inhibitor costs 
were $12,195 (±$8,517). For each cost variable (total health care, RA-related and TNF 
inhibitor costs), costs incurred by patients on ETN were significantly lower (p< 0.01) 
than those incurred by ADA patients but significantly higher (p< 0.01) than those 
incurred by IFX patients. Persistence to index TNF inhibitor therapy and likelihood 
to switch or discontinue were comparable among groups. Duration of medication 
use (i.e. persistence) prior to switching or discontinuation of index therapy was also 
comparable among groups. cOnclusiOns: The data suggest comparable medica-
tion use patterns but significantly different health care utilization costs among 
Texas Medicaid RA patients on ETN, IFX or ADA.
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Utilizing nordic regiStrieS to SUPPort health econoMicS reSearch 
in rheUMatic diSeaSeS
Miller H.
Karolinska Institutet, Stockholm, Sweden
Objectives: Rheumatic diseases are often characterized by pain and disability. 
Many pharmaceuticals are available for their treatment and a considerable number 
of health economic(HE) studies have been published. Nordic countries maintain 
long-term comprehensive disease and drug registries. HE analyses, particularly 
those which are based on registry-data, can provide important information for 
health care decision makers. The primary objective of this study is to systematically 
review HE analyses of rheumatic diseases which utilize Nordic registry-data, and 
to provide a descriptive and critical analysis of this strategy. MethOds: Published 
literature was identified by searching the following databases: MEDLINE; EMBASE; 
Cochrane Library and Health Economic Evaluations Database; and PubMed. Search 
terms were pertinent to rheumatic diseases and HE. One reviewer screened and 
subsequently extracted data from studies which fulfilled inclusion/exclusion cri-
teria. References and citation search was done on included studies. Results: 45 
HE studies utilized Nordic registry-data. Studies were relevant to Sweden(n= 26), 
Norway(n= 11), Finland(n= 4) and Denmark(n= 4). Study types were modeling(n= 13), 
costing(n= 8), work/productivity(n= 6), quality-of-life(n= 13), and a combination 
of HE outcomes(n= 5). Registry data was used within the studies to characterize 
patients in regards to clinical(n= 29), demographic(n= 20), utility(n= 18) and cost/
drugs (70.75%). The most commonly prescribed anti-rheumatic drugs were NSAIDs 
and Analgesics (75.60%), DMARDs (20.40%) and Corticosteroids (4.00%). Multiple 
logistic regression analysis showed that females (OR: 0.55; 95% CI: 0.32-0.95), indi-
viduals aged group 18 to 64 years (OR: 0.48; 95% CI: 0.29-0.78) were less likely to 
receive anti-rheumatic drugs, whereas those seeking care from rheumatologists 
(OR: 4.38; 95% CI: 2.19-8.77) and those with multiple previous visits (OR: 1.43; 95% 
CI: 1.26-1.62) were more likely to receive anti rheumatic drugs. cOnclusiOns: 
Most (7 out of 10) visits for the RA involved use of anti-rheumatic drugs. Drug use 
patterns varied across age, gender, physician specialty, and previous use of health 
care. Further research is needed to evaluate the variation across drug classes 
for RA.
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relationShiP BetWeen the dUration oF rheUMatology Practice 
exPerience and likelihood oF USe and PercePtion toWardS 
BioSiMilarS in rheUMatoid arthritiS (ra) arena
Narayanan S.
Ipsos Healthcare, Columbia, MD, USA
Objectives: To assess the relationship between duration of rheumatology practice 
experience and rheumatologist perception towards biosimilars and the likelihood of 
use of biosimilars to manage RA patients in the European Union (EU), Brazil, Japan 
and China. MethOds: A multi-country cross-sectional survey was conducted in 
top-5 EU countries (UK/Germany/Spain/France/Italy), Brazil, Japan and China in 
April/May 2013 using an online physician panel in the respective geographies; rheu-
matologists were randomly selected for survey participation to be geographically 
representative in select countries/regions. Surveys assessed the rheumatologist 
perceptions of biosimilars in terms of factors that would prevent them from using 
biosimilars among their biologic-eligible RA patients, and their likelihood of use of 
biosimilars. Summary statistics are reported across the markets, stratified by years 
of rheumatology-practice-experience. Results: 173 rheumatologists participated 
in the survey (5EU-58%, Brazil-23%, Japan-11% and China-9%); years of experience 
practicing rheumatology (across the markets) was: < = 10yrs:26%, 11-20yrs:42%, 
> 20yrs:32%. Mean RA patient-volume/year based on rheumatology-practice-expe-
rience was: < = 10yrs:264, 11-20yrs:323, > 20yrs:270. Likelihood of prescribing a bio-
similar product to eligible RA patients differed by rheumatology-practice-experience 
(< = 10yrs/11-20yrs/> 20yrs): definitely-13%/13%/5%; highly likely-27%/42%/39%; may 
be/not sure-44%/36%/38%; less/not likely-16%/10%/18%. Perceived duration of use of 
biosimilars in a small group of patients before prescribing it in larger scale was (by 
rheumatology-practice-experience < = 10yrs/11-20yrs/> 20yrs): 1-2yrs:53%/56%/43%, 
3-5yrs:16%/11%/14%, 6-10yrs:2%/1%/2%, > 10yrs:4%/4%/5%; not-sure:24%/28%/36%. 
Key factors noted by rheumatologists that would prevent them from using bio-
similars were (by rheumatology-practice-experience < = 10yrs/11-20yrs/> 20yrs): 
Doubts in similarity to original molecule(56%/63%/59%), inadequate safety/effi-
cacy profile/data(47%/57%/52%), lack of long-term data(42%/39%/57%), lack of 
national guidelines recommending the use of biosimilars(40%/38%/34%), lack of 
data from local country/market(40%/31%/25%), lack of trust/confidence in manu-
facturer(24%/25%/27%). cOnclusiOns: Rheumatologists perceptions varied based 
on their practice-experience; those with < = 10yrs of practice-experience reported 
the least likelihood of prescribing biosimilars, and a higher proportion of them cited 
national treatment guidelines and lack of data from local country/market among 
key reasons preventing biosimilar use.
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coMPariSon oF clinical characteriSticS oF PatientS With 
rheUMatoid arthritiS (ra) receiving a Biologic MonotheraPy and 
Biologic coMBination theraPy in the United StateS
Narayanan S.1, Lu Y.2, Hutchings R.2, Baynton E.2
1Ipsos Healthcare, Columbia, MD, USA, 2Ipsos Healthcare, London, UK
Objectives: To assess the clinical characteristics of patients with RA who received 
a biologic monotherapy (Mono) and biologic combination therapy (Combo: 
Biologic+DMARDs) in the US. MethOds: A multi-country multi-center medical 
chart-review study of RA patients was conducted between Nov2012-Jan2013 among 
physicians (mainly rheumatologists) in hospitals and private practices to collect 
de-identified data on patients who were recently treated with a biologic as part of 
usual care. Physicians were screened for duration of practice (3-30 yrs) and patient 
volume (incl. > 2RA biologic patients/week) and recruited from a large panel to be 
geographically representative of the US. Eligible patient charts (> 5) were randomly 
selected from a sample of prospective patients visiting each center/practice dur-
ing the screening period. Physicians abstracted patient diagnosis, treatment pat-
terns/dynamics and patient symptomatology/disease status. This analysis focused 
on patients currently on Mono and Combo biologics. Results: 919 eligible RA 
patients were included in the analysis; Mono patients: 353 (38%), Combo patients: 
566 (62%). Patient characteristics included (Mono/Combo): mean age:47.4/57.8; 
female:50%/61%; mean weight(Kg):75.7/78.0; top-3 comorbidities: obesity(17%/20%), 
dyslipidemia(14%/22%, depression/anxiety:9%/16%. Time between RA diagnosis 
and recent office visit (Mono/Combo):77.1/78.5months; number of biologic-lines 
of therapy received (Mono/Combo): 1st-line-80%/70%, 2nd-line-15%/20%, > = 3rd-
line-5%/11%; top-4 biologics used across the two patient groups were: adalimumab/
etanercept/infliximab/abatacept. Among patients with data-availability, current lab 
& disease-severity measures were (Mono/Combo): ESR(mm/h)-23.7/25.0; CRP(mg/
dl)-2.6/3.4; rheumatoid factor (positive%):38%/54%; anti-CCP (positive%):31%/45%; 
overall disease-stage per physician-judgment: mild-67%/62%, moderate-29%/33%, 
severe-4%/5%; mean-HAQ:0.7/0/9; mean-DAS28:2.3/3.0; mean tender joint count: 
2/3/3.4; mean swollen joint count:1.4/2.5. cOnclusiOns: In this cohort of RA 
patients in the US, over 60% of Mono and Combo patients had mild disease per 
physician judgment and a majority of them were on 1st line treatment; lab meas-
ures and joint counts indicated only slightly higher disease burden among Combo 
patients. Impact of specific biologic treatments on observed patterns and the need 
for therapeutic sequencing may warrant scrutiny.
